The Patent Finder

Wilex AG

Also on record
Records under this name other than the patents Wilex AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.

Back to Wilex AG

PatentTitleStatus Expires Confidence
US 8,492,520Binding epitopes for G250 antibody
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,691,375Adjuvant theraphy of G250-expressing tumors
Term ended
Term ended Apr 12, 2026 · From the USPTO record
Term endedTerm ended Apr 12, 2026From the USPTO record
US 7,884,206Method for producing 3-amidinophenylalanine derivatives
Term ended
Term ended Sep 13, 2025 · From the USPTO record
Term endedTerm ended Sep 13, 2025From the USPTO record
US 9,605,075Hybridoma cell line G250 and its use for producing monoclonal antibodies
Term ended
Term ended Mar 29, 2025 · From the USPTO record
Term endedTerm ended Mar 29, 2025From the USPTO record
US 7,608,623Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
Term ended
Term ended Nov 16, 2024 · From the USPTO record
Term endedTerm ended Nov 16, 2024From the USPTO record
US 8,828,381Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
Term ended
Term ended Jun 4, 2024 · From the USPTO record
Term endedTerm ended Jun 4, 2024From the USPTO record
US 7,807,681Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
Term ended
Term ended May 26, 2024 · From the USPTO record
Term endedTerm ended May 26, 2024From the USPTO record
US 7,659,396Method for the production of phenylalanine derivatives
Term ended
Term ended Apr 23, 2024 · From the USPTO record
Term endedTerm ended Apr 23, 2024From the USPTO record
US 7,247,724Method for the production of phenylalanine derivatives
Term ended
Term ended Dec 15, 2023 · From the USPTO record
Term endedTerm ended Dec 15, 2023From the USPTO record
US 7,632,496Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
Formerly held
Term ended
Term ended Jul 14, 2023 · From the USPTO record
Term endedTerm ended Jul 14, 2023From the USPTO record
10 of 41 patents shown.
Pro members see all 41.
Pro members: see all 41 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited